{
    "nct_id": "NCT03993353",
    "official_title": "A Phase II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "inclusion_criteria": "* Patients (at least 18 years of age) must have recurrent or metastatic squamous cell carcinoma of the head and neck.\n* Presence of measurable disease.\n* Life expectancy of greater than 12 weeks\n* Patients must have normal organ and marrow function\n\nSelected\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy with an PD-1 or PD-L1 inhibitor in the recurrent or metastatic setting\n* Uncontrolled central nervous system metastases (stable metastases permitted)\n* Active autoimmune disease\n* Chemotherapy ≤28 days prior to first administration of study treatment and/or monoclonal antibody ≤8 weeks prior to first administration of study treatment.\n* Prior daily use of tadalafil or other long-acting PDE5 inhibitors for one month or greater within 3 months of trial enrollment\n* Current use of all other long-acting PDE5 inhibitors.\n* Known severe hypersensitivity to tadalafil or any of the excipients of this product\n* Current treatment with nitrates\n* Current systemic treatment with a potent cytochrome P450 3A4 (CYP3A4) inhibitor such as ketoconazole or ritonavir.\n* Current treatment with guanylate cyclase (GC) stimulators such as riociguat.\n* History of hypotension and/or blindness and/or sensorineural hearing loss during prior treatment with tadalafil or other PDE-5 inhibitors\n* History of known hereditary degenerative retinal disorders, including retinitis pigmentosa\n* Prior history of non-arteritic anterior ischemic optic neuropathy\n* Pregnant or breastfeeding; a negative pregnancy test is required within 14 days of randomization for all women of childbearing potential.\n* History of stroke within prior 6 months.\n* History of acute myocardial infarction within prior 3 months, uncontrolled angina, uncontrolled arrhythmia, or uncontrolled congestive heart failure\n* Left ventricular outflow obstructions, such as aortic stenosis and idiopathic hypertrophic subaortic stenosis\n* Angina requiring treatment with long-acting nitrates\n* Angina requiring treatment with short-acting nitrates within 90 days of planned tadalafil administration\n* Unstable angina within 90 days of visit 1 (Braunwald 1989)\n* Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention\n* History of any of the following coronary conditions within 90 days of planned tadalafil administration:\n\n  * Myocardial Infarction\n  * Coronary artery bypass graft surgery\n  * Percutaneous coronary intervention (for example, angioplasty or stent placement)\n  * Any evidence of heart disease (NYHA ≥ Class II as defined in Protocol Attachment LVHG.3) within 6 months of planned tadalafil administration\n* Concurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration of >10 mg/day of prednisone or equivalent)\n* Prior organ transplantation\n* Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).",
    "miscellaneous_criteria": "Selected"
}